Enanta Stock Falls 19% After Fiscal Q4 Results Show Revenue Decline and Wider Quarterly Loss

The drop followed an 8-K press release reporting a fourth-quarter net loss of $23.7 million and CEO retirement plans announced in October.

Plastic bottles with yellow liquid substance of shampoo, shower gel or soap standing in rows on assembly line at factory. Res
Photo: Cast Of Thousands/Shutterstock.com

Key points

  • Enanta fell 18.6% Tuesday after fiscal Q4 revenue and loss results were released Nov. 16
  • Q4 revenue was $12.9 million, down from $15.1 million a year earlier
  • Q4 net loss was $23.7 million, or $0.81 per diluted share, versus $0.87 a year earlier
  • Cash and marketable securities totaled $194.5 million; company says runway extends into fiscal 2029

Enanta Pharmaceuticals (Nasdaq: ENTA) fell 18.6% on Tuesday, Nov. 17, 2026, closing at $8.69 from a previous close of $10.67, while the S&P 500 ETF (SPY) slipped 1.01%. Volume ran at 3.5 times its usual level. The session followed the company's release of fiscal fourth-quarter and full-year results, furnished in an 8-K on Nov. 16. The filing did not include any statement from management about how investors should read the results, and no analyst actions were reported for the session.

Revenue fell and the quarterly loss widened

Total revenue was $12.9 million for the quarter ended Sept. 30, 2026, down from $15.1 million a year earlier. The company attributed the decline to lower AbbVie sales of MAVYRET/MAVIRET, the hepatitis C regimen from which Enanta earns royalties. The net loss for the quarter was $23.7 million, or $0.81 per diluted share, compared with a net loss of $18.7 million, or $0.87 per share, a year earlier. The per-share loss was narrower, but the dollar loss was wider.

Spending and cash position

Research and development expenses rose to $26.1 million in the quarter from $23.8 million, driven by RSV trials. Cash, cash equivalents and marketable securities totaled $194.5 million at Sept. 30, 2026. Enanta said that cash, together with its retained royalties, should fund operations into fiscal 2029.

Leadership transition and pipeline timing

Chief Executive Jay R. Luly, Ph.D., plans to retire by February 2027, a change first announced in October. Tara L. Kieffer, Ph.D., was named chief operating officer. The company also pushed the expected timing of topline data from its EDP-978 Phase 1 trial to the first quarter of 2027, and the IND filing for EDP-903 to the second quarter of 2027.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

Other stock movers this week

Latest earnings results →
ENTA page →

Filings, figures and price history are on the Enanta Pharmaceuticals page.